期刊文献+

三七总皂苷对慢性马兜铃酸肾病大鼠体内抗氧化作用的研究 被引量:4

Research on antioxidation of panax notoginseng saponins in rats of chronic aristolochic acid nephropathy
下载PDF
导出
摘要 目的观察三七总皂苷对慢性马兜铃酸肾病损害大鼠模型抗氧化作用。方法 Wistar大鼠随机分为正常对照组、模型组及三七总皂苷低、中、高剂量组。造模大鼠按马兜铃酸20 mg.kg-1.d-1的剂量灌服关木通浸膏,1周后改为按马兜铃酸15 mg.kg-1.d-1的剂量灌服,4 h后三七总皂苷各组灌服不同剂量三七总皂苷溶液(100、200、400 mg.kg-1.d-1),模型组灌服等体积生理盐水。分别于实验第12、16、20周测定大鼠肾组织SOD活性、MDA含量及GHS含量。结果三七总皂苷可升高慢性马兜铃酸肾病大鼠肾组织SOD活性和GSH-PX含量,明显降低肾组织中MDA(P<0.05)。结论三七总皂苷对慢性马兜铃酸肾病大鼠损伤起保护作用。 Objective To observe the antioxidation of panax notoginseng saponins(PNS) in rats of chronic aristolochic acid nephropathy(ANN).Methods Wistar rats were randomly divided into control group,model group and panax notoginseng saponins groups(low,medium and high dose).The model group and PNS group were given the extract of Caulis oristolochiae Manshuriensis(according to the dose of aristolochic acid 20 mg·kg-1·d-1)by intragastric administer for one week.And then the doses were changed of 15 mg·kg-1·d-1.Four hours later,the PNS group was subdivided into three groups and administered PNS(100,200,400 mg·kg-1·d-1)respectively.The model group was given equal volume of normal sodium.The urine and blood were collected at the end of the 12th,16th,20th week.Changes of the activity of superoxide dismutase(SOD) and the content of malondialdehyde(MDA) and Glutathione peroxidase(GSH-PX) in kidney were observed.Results PNS could enhance activity of SOD and GSH-PX,reduce the content of MDA in kidney(P0.05).Conclusion PNS had protective effects on rats of chronic aristolochic acid nephropathy.
出处 《齐鲁药事》 2011年第4期190-191,共2页 qilu pharmaceutical affairs
关键词 三七总皂苷 马兜铃酸肾病 抗氧化 动物实验 Panax notoginseng saponins(PNS) Aristolochic acid nephropathy Antioxidative Animal experiment
  • 相关文献

参考文献7

二级参考文献19

  • 1高艳丽,谌贻璞,董鸿瑞,丛笑.慢性马兜铃酸肾病肾间质纤维化的实验研究[J].中华医学杂志,2004,84(17):1496-1496. 被引量:2
  • 2高艳丽,谌贻璞,董鸿瑞,丛笑.慢性马兜铃酸肾病肾间质纤维化发病机制的初步探讨[J].中华肾脏病杂志,2005,21(1):31-35. 被引量:41
  • 3[1]Tang WW, Van CY, Qi M. Myofibroblast and α1 ( Ⅲ ) collagen expression in experimental tubulointerstitial nephritis.Kidney Iht 1997 ;51: 926-931.
  • 4[2]Badid C, Mounier N, Costa AM, et al. Role of myofibroblasts during normal tissue repair and excessive scarring: Interest of their assessment in nephropathies. Histol Histopathol 2000; 15: 269-280.
  • 5[3]Strutz F, Okada H, Cecilia WL, et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995; 130: 387-391.
  • 6[4]Okada H, Danoff TM, Kalluri R, et al. Early role of FSP1 in epithelial-mesenchymal transformation. Am J Physiol 1997;273: F563-F574.
  • 7[5]Yee YN, Huang TP, Yang WC, et al. Tubular epithelialmyofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998 ;54:864-876.
  • 8[6]Fan JM, Yee YN, Prudence AH, et al. Transforming growth factor-β regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999; 56: 1455-1467.
  • 9[7]Fan JM, Xiao RH, Yee YN, et al. Interleukin-1 induces tubular epithelial-myofibroblast transdifferentiation through a transforming growth factor-β1-depensent mechanism in vitro.Am J Kidney Dis 2001 ;37:820-831.
  • 10[8]Schurch W, Seemayer TA, Gabbiani G. The myofibroblast:a quarter century after its discovery. Am J Surg Pathol 1998;22 (2): 141-147.

共引文献158

同被引文献83

引证文献4

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部